Marion Subklewe

Statistics

Publications

Citations

566

H-Index

Active since

2018

Affiliations

Ludwig-Maximilians-Universität München(Current)

LMU Klinikum

The University of Texas MD Anderson Cancer Center

Vall d'Hebron Hospital Universitari

Vall d'Hebron Institut de Recerca

Marion Subklewe is an author at Ludwig-Maximilians-Universität München specializing in oncology, hematologic malignancy therapy, and cancer immunotherapy.

Publications per year

2018–2024

Publications

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Gloria Iacoboni, Vı́ctor Navarro, Ana África Martín‐López et al. · Journal of Clinical Oncology · 2023 · 125 citations · Full text

Medicine, Immunology, Oncology +14

Cooperative CAR targeting to selectively eliminate AML and minimize escape

Sascha Haubner, Jorge Mansilla‐Soto, Sarah Nataraj et al. · Cancer Cell · 2023 · 107 citations · Full text

Medicine, Immunology, Oncology +17

Impaired function and delayed regeneration of dendritic cells in COVID-19

Elena Winheim, Linus Rinke, Konstantin Lutz et al. · PLoS Pathogens · 2021 · 91 citations · Full text

Life Sciences, Immunology, Infectious Diseases +14

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Farhad Ravandi, Anthony S. Stein, Hagop M. Kantarjian et al. · Blood · 2018 · 80 citations

Medicine, Hematology, Oncology +17

Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study

Farhad Ravandi, Marion Subklewe, Roland B. Walter et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2024 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–5 of 11